Gilead's new drug keeps 56 percent of lymphoma trial patients alive - Reuters

Medical Xpress

Gilead's new drug keeps 56 percent of lymphoma trial patients alive Reuters (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaPR Newswire (press release) Phase 2 CAR-T study reports significant remission rates at 15-month follow upEurekAlert (press release) Global CAR T therapy trial shows high rates of durable remission for NHLMedical Xpress Markets Insider -Financial Times all 9 news articles »

from Health - Google News http://ift.tt/2jliYoo

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study - Reuters

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study Reuters (Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study ... and more »

from Health - Google News http://ift.tt/2iL4z0Z

Scholarship for Muslim women honors pioneering scientist - Washington Post

Washington Post

Scholarship for Muslim women honors pioneering scientist Washington Post DETROIT — When it came to pursuing a scientific career, Tasneem Essader encountered forces pulling her in and pushing her away: She drew inspiration from her mother's work in chemistry, but initial discouragement from her engineer father, who thought ... and more »

from Health - Google News http://ift.tt/2C1F5EQ

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study - Reuters

Endpoints News

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study Reuters (Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study ... Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 ...Business Wire (press release) all 4 news articles »

from Health - Google News http://ift.tt/2C35JgX

Gilead's new drug keeps 56 pct of lymphoma trial patients alive - Reuters

Financial Times

Gilead's new drug keeps 56 pct of lymphoma trial patients alive Reuters Dec 10 (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaMarkets Insider Gilead dispels doubts with Car-T cancer drug trial resultsFinancial Times all 7 news articles »

from Health - Google News http://ift.tt/2AUBP0c